Mersana Therapeutics Inc.

MRSN | NASDAQ

Price Alert Chart Builder DCF Calculator

$29.08

$0 (0.00%)

At close: Jan 6, 2026, 4:00 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

Market Data

Market Cap $145.36M

Enterprise Value $91.27M

Beta 0.43

Average Volume 125.27K

Shares Outstanding (Diluted) N/A

Shares Change YoY 1.59%

Institutional Ownership 63.75%

Exchange NASDAQ

ISIN US59045L2051

Price Performance

Price Change 1M 3.5%

Price Change 3M 193.4%

Price Change 6M 239.3%

Price Change YTD 0.3%

Price Change 1Y 61.6%

Price Change 3Y N/A

Price Change 5Y -94.5%

1M CAGR (ann.) 5.7%

1Y CAGR (ann.) -16.9%

5Y CAGR (ann.) -46.7%

All-Time CAGR -25.3%

Valuation

PE Ratio -2.06

Forward PE N/A

PEG Ratio -0.35

Forward PEG 0.43

PS Ratio 4.38

Forward PS 11.40

PB Ratio -2.44

P/FCF Ratio -1.95

P/Adj. FCF Ratio -1.74

P/OCF Ratio -2.63

EV/Sales 2.75

EV/EBIT -1.52

EV/EBITDA -1.54

EV/FCF -1.23

Earnings Yield -48.5%

FCF Yield -51.2%

Adj. FCF Yield -57.5%

Financial Health

Net Cash $54.1M

Total Debt $2.29M

Cash & Short-Term Investments $56.39M

Total Assets $62.69M

Current Ratio 1.39

Quick Ratio 1.39

Debt / Equity Ratio -0.04

Debt / EBITDA -0.04

Debt / FCF -0.03

OCF / Debt -32.43

Interest Coverage -28.52

Altman Z-Score -22.86

Piotroski F-Score 4

Margins & Profitability

Gross Profit Margin 98.3%

Operating Profit Margin -180.5%

EBITDA Margin -317.7%

Net Profit Margin -332.7%

FCF Margin -224.1%

Adj. FCF Margin -252.1%

SBC / Revenue 35.2%

SBC Impact (per share) -12.5%

Returns

Return on Assets -89.3%

Return on Equity 117.0%

Return on Invested Capital -242.1%

Return on Capital Employed -270.7%

Return on Tangible Assets -89.3%

Historical Growth (CAGR)

Revenue CAGR 3Y 40.7%

Revenue CAGR 5Y 107.6%

Revenue CAGR 10Y N/A

EPS CAGR 3Y 61.8%

EPS CAGR 5Y 33.1%

EPS CAGR 10Y N/A

FCF CAGR 3Y 48.1%

FCF CAGR 5Y 2.6%

FCF CAGR 10Y N/A

Analyst Forecasts

Analyst Rating Buy

Analyst Count 19

EPS Growth Next 3Y 36.3%

Revenue Growth Next 3Y 84.5%

Earnings Date Mar 1, 2026

EPS Estimate (next Q) -$3.05

EPS Growth Est (next Q) 11.1%

Revenue Est (next Q) $4.6M

Revenue Growth Est (next Q) -71.9%

Fair Value Estimates

Graham Number N/A

Graham Upside N/A

Lynch Fair Value N/A

Lynch Upside N/A

Price Target $10

Price Target Upside -65.6%

Cash Flow

Operating Cash Flow $-74.37M

Free Cash Flow $-74.37M

Adj. Free Cash Flow $-83.64M

FCF Per Share -$11.05

OCF Per Share -$11.05

OCF/S Ratio -327.7%

Income Statement

Revenue $33.18M

Gross Profit $21.88M

Operating Income $-59.9M

EBITDA $-59.18M

Net Income $-70.08M

EPS (Diluted) -$14.09

Revenue / Employee $325.29K

Profit / Employee $-687.07K

Employees 102